Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA accepts BLA for thyroid eye treatment
➤ Breakthrough Therapy Designation granted to investigational neuroprotective for optic neuropathies
➤ FDA issues complete response letter for wet AMD BLA resubmission
➤ Biosimilar approved for retinal therapies
➤ FDA approves IND for corneal genome editing program
➤ Study: ‘largest prospective trial ever’ on postcataract endophthalmitis prophylaxis
➤ Complimentary access to video journal
➤ Company news
➤ ASCRS news and events
➤ FDA review extended for dry eye disease treatment
➤ Key data gathered for expected NDA submission
➤ Phase 2b results for GA treatment
➤ Phase 3 studies discontinued for thyroid eye disease
➤ ASCRS news and events
➤ FDA grants IDE for synthetic endothelial layer study
➤ NDA submission for wet AMD treatment advances
➤ Positive feedback moves forward NDA submission plans
➤ Company news
➤ ASCRS news and events
The performance of a pars plana anterior vitrectomy can be an essential skill in select circumstances. Two physicians discussed when this approach may best be utilized, benefits of it, and other nuances.
➤ FDA approves treatment for macular edema following RVO
➤ New cyclosporine product receives approval for dry eye
➤ First human implant of 3D-bioprinted cornea
➤ Topline results from Phase 3 trial for Stargardt disease
➤ First patient treated with IDE glaucoma therapy
➤ Enrollment complete for Phase 2 trial for geographic atrophy treatment
➤ First patient implanted with investigational glaucoma shunt in trial
➤ Positive review of Phase 3 pivotal trial for AMD
➤ Company news
➤ ASCRS news and events
➤ 510(k) clearance granted to auto kerato-refracto tonometer
➤ First patient dosed with gene therapy for Best disease
➤ Long-term data shows therapy delays geographic atrophy progression
➤ Lead gene therapy candidate to treat wet AMD and DME announced
➤ FDA accepts BLA resubmission
➤ Company news
➤ ASCRS news and events
➤ Meeting with FDA to advance therapy for Leber congenital amaurosis
➤ 36-month data from first-in-human bimatoprost-IOL system
➤ 20-week data from study evaluating treatment for patients with macular edema secondary to inflammation
➤ Interim data from Phase 1/2 trial for wet AMD therapy
➤ Company news
➤ ASCRS news and events
➤ Topline Phase 3 results for low-dose atropine drop
➤ 12-month data from prospective pilot study assessing aqueous shunt
➤ 5-year follow-up data supports safety, tolerability of investigational retinitis pigmentosa treatment.
➤ Randomization achieved in registrational trial for wet AMD therapy
➤ BLA submitted for thyroid eye disease treatment
➤ Company news
➤ ASCRS news and events
➤ Complete response letter issued for low-dose atropine drop
➤ Extension study shows reduced GA growth with intravitreal treatment
➤ Durable, 3-year vision improvements seen with optogenetic therapy
➤ Preclinical data supports long-acting nature of investigational anti-VEGF for wet AMD
➤ Company news
➤ ASCRS news and events
➤ FDA approves epithelium-on crosslinking treatment
➤ 12-month results from Phase 1/2 trial evaluating regenerative cell therapy for corneal endothelial disease
➤ Phase 3 data supports nonsteroidal treatment for uveitic macular edema
➤ FDA approves IDE for glaucoma device
➤ Company news
➤ ASCRS news and events
